The story of Sildenafil presents a nuanced case for investors in the pharmaceutical sector. While initially a blockbuster success, producing billions, the intellectual property expiration and the subsequent flood of off-brand alternatives have significantly affected revenue. This raises questions about the long-term viability of related medicati… Read More